Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? European journal of cancer (Oxford, England : 1990) Houot, R. n., Levy, R. n., Cartron, G. n., Armand, P. n. 2020; 136: 4–6


A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.

View details for DOI 10.1016/j.ejca.2020.06.017

View details for PubMedID 32619884

View details for PubMedCentralID PMC7315961